Heightened Circulating Interferon-Inducible Chemokines, and Activated Pro-Cytolytic Th1-Cell Phenotype Features Covid-19 Aggravation in the Second Week of Illness

Covid-19 features a delayed onset of critical illness occurring approximately one week from the beginning of symptoms, which corresponds to the bridging of innate and adaptive immunity. We reasoned that the immune events occurring at the turning point of disease might mark the direction toward pathogenic versus protective inflammatory responses. Subjects with either severe (s; PaO2/FiO2 ratio <200) or mild (m; PaO2/FiO2 ratio>300) Covid-19 were enrolled. A range of chemokines and cytokines as well as reactive oxygen species (ROS) were measured in plasma. Dendritic and NK cell frequency, monocyte and B-/T-cell phenotype and SARS-CoV-2-specific T-cell responses were assessed in PBMC. Twenty mCovid-19 and 20 sCovid-19 individuals were studied. sCovid-19 patients displayed higher non-classical monocytes, plasma chemokines (CXCL8, CXCL9, CXCL10), cytokines (IL-6, IL-10), and ROS versus mCovid-19. sCovid-19 also showed significantly increased activated CD38+HLA-DR+ T-lymphocyte, and granzyme-B+/perforin+ pro-cytolytic T-cells. All Covid-19 patients showed SARS-CoV-2 specific-T-cell response with a predominance of Th1 bi- or trifunctional IFN-γ/IL-2/TNF-α-expressing CD4+, while no difference according to disease severity was observed. Severe Covid-19 features heightened circulating IFN-inducible chemokines and activated pro-cytolytic Th1 cell phenotype in the second week of illness, yet SARS-CoV-2-specific responses are similar to that of mild illness. Altogether, our observations suggest Th1 polarization coupled to higher cytolytic profile in sCovid-19 as correlate of disease pathogenesis and as potential targets to be investigated in the roadmap to therapy and vaccine development.

[1]  Dennis Andersson,et al.  Ensuring trust in COVID-19 data , 2021, Medicine.

[2]  Y. Hu,et al.  Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China , 2020, The Lancet.

[3]  A. Sette,et al.  Phenotype and kinetics of SARS-CoV-2-specific T cells in COVID-19 patients with acute respiratory distress syndrome , 2020, Science Immunology.

[4]  Shakiba Darvishalipour,et al.  COVID-19: combining antiviral and anti-inflammatory treatments , 2020 .

[5]  M. Chiarini,et al.  Immune response in children with COVID‐19 is characterized by lower levels of T‐cell activation than infected adults , 2020, European journal of immunology.

[6]  F. Galluccio,et al.  Treatment algorithm for COVID-19: a multidisciplinary point of view , 2020, Clinical Rheumatology.

[7]  J. Greenbaum,et al.  Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals , 2020, Cell.

[8]  B. Lipworth,et al.  Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19 , 2020, Journal of Allergy and Clinical Immunology.

[9]  T. C. I. team Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020 .

[10]  Catherine M. Brown,et al.  Clinical and virologic characteristics of the first 12 patients with coronavirus disease 2019 (COVID-19) in the United States , 2020, Nature Medicine.

[11]  M. Girardis,et al.  Marked T cell activation, senescence, exhaustion and skewing towards TH17 in patients with COVID-19 pneumonia , 2020, Nature Communications.

[12]  M. Netea,et al.  Complex Immune Dysregulation in COVID-19 Patients with Severe Respiratory Failure , 2020, Cell Host & Microbe.

[13]  Zhiyong Ma,et al.  Characteristics of Peripheral Lymphocyte Subset Alteration in COVID-19 Pneumonia , 2020, The Journal of infectious diseases.

[14]  Taojiao Wang,et al.  Clinical and immunologic features in severe and moderate Coronavirus Disease 2019. , 2020, The Journal of clinical investigation.

[15]  Zhigang Tian,et al.  Functional exhaustion of antiviral lymphocytes in COVID-19 patients , 2020, Cellular & Molecular Immunology.

[16]  Xin Zhou,et al.  Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With Coronavirus Disease 2019 Pneumonia in Wuhan, China , 2020, The Journal of Emergency Medicine.

[17]  J. Xiang,et al.  Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study , 2020, The Lancet.

[18]  K. Yuen,et al.  Clinical Characteristics of Coronavirus Disease 2019 in China , 2020, The New England journal of medicine.

[19]  Ivan Griffin,et al.  COVID-19: combining antiviral and anti-inflammatory treatments , 2020, The Lancet Infectious Diseases.

[20]  Jiyuan Zhang,et al.  Pathological findings of COVID-19 associated with acute respiratory distress syndrome , 2020, The Lancet Respiratory Medicine.

[21]  Chuan Qin,et al.  Dysregulation of immune response in patients with COVID-19 in Wuhan, China , 2020, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[22]  Yan Zhao,et al.  Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. , 2020, JAMA.

[23]  Ting Yu,et al.  Epidemiological and clinical characteristics of 99 cases of 2019 novel coronavirus pneumonia in Wuhan, China: a descriptive study , 2020, The Lancet.

[24]  J. Joh,et al.  Immune Responses to Middle East Respiratory Syndrome Coronavirus During the Acute and Convalescent Phases of Human Infection , 2018, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America.

[25]  Hideo Baba,et al.  CXCL9, CXCL10, CXCL11/CXCR3 axis for immune activation - A target for novel cancer therapy. , 2018, Cancer treatment reviews.

[26]  F. Welch,et al.  Causes and Consequences , 2017, Nature.

[27]  P. G. Choe,et al.  Clinical Progression and Cytokine Profiles of Middle East Respiratory Syndrome Coronavirus Infection , 2016, Journal of Korean medical science.

[28]  A. Bertoletti,et al.  Understanding the T cell immune response in SARS coronavirus infection , 2012, Emerging Microbes & Infections.

[29]  R. Baric,et al.  SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon , 2012, Current Opinion in Virology.

[30]  Jincun Zhao,et al.  Age-related increases in PGD(2) expression impair respiratory DC migration, resulting in diminished T cell responses upon respiratory virus infection in mice. , 2011, The Journal of clinical investigation.

[31]  Jincun Zhao,et al.  T Cell Responses Are Required for Protection from Clinical Disease and for Virus Clearance in Severe Acute Respiratory Syndrome Coronavirus-Infected Mice , 2010, Journal of Virology.

[32]  Christopher D. Paddock,et al.  Cellular Immune Responses to Severe Acute Respiratory Syndrome Coronavirus (SARS-CoV) Infection in Senescent BALB/c Mice: CD4+ T Cells Are Important in Control of SARS-CoV Infection , 2009, Journal of Virology.

[33]  Jincun Zhao,et al.  Evasion by Stealth: Inefficient Immune Activation Underlies Poor T Cell Response and Severe Disease in SARS-CoV-Infected Mice , 2009, PLoS pathogens.

[34]  A. McMichael,et al.  T Cell Responses to Whole SARS Coronavirus in Humans1 , 2008, The Journal of Immunology.

[35]  V. Appay,et al.  Immune activation and inflammation in HIV‐1 infection: causes and consequences , 2008, The Journal of pathology.

[36]  R. Medzhitov,et al.  Not so fast: adaptive suppression of innate immunity , 2007, Nature Medicine.

[37]  Hong Tang,et al.  Adaptive immune cells temper initial innate responses , 2007, Nature Medicine.

[38]  Ali Danesh,et al.  Interferon-Mediated Immunopathological Events Are Associated with Atypical Innate and Adaptive Immune Responses in Patients with Severe Acute Respiratory Syndrome , 2007, Journal of Virology.

[39]  Mario Roederer,et al.  HIV nonprogressors preferentially maintain highly functional HIV-specific CD8+ T cells. , 2006, Blood.

[40]  G. Pantaleo,et al.  Functional signatures of protective antiviral T‐cell immunity in human virus infections , 2006, Immunological reviews.

[41]  S. Perlman,et al.  Immunopathogenesis of coronavirus infections: implications for SARS , 2005, Nature Reviews Immunology.

[42]  Peter Hunt,et al.  Immune activation set point during early HIV infection predicts subsequent CD4+ T-cell changes independent of viral load. , 2004, Blood.

[43]  S. Rowland-Jones,et al.  Skewed maturation of memory HIV-specific CD8 T lymphocytes , 2001, Nature.

[44]  F. Sallusto,et al.  Two subsets of memory T lymphocytes with distinct homing potentials and effector functions , 1999, Nature.

[45]  J V Giorgi,et al.  Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. , 1999, The Journal of infectious diseases.

[46]  Mary Linnea Nelson,et al.  Health Care Worker Incidents Reported in a Rural Health Care Facility , 1996, AAOHN journal : official journal of the American Association of Occupational Health Nurses.